Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Inventory data on file, last reported at $84.0 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 28.12% year-over-year to $84.0 million; the trailing twelve-month figure through Mar 2026 stood at $84.0 million (up 28.12% YoY), and the FY2025 full-year result was $82.7 million, up 5.36% from the prior year.
• Inventory for Q1 2026 stood at $84.0 million, up from $82.7 million in the prior quarter.
• Across five years, Inventory topped out at $131.9 million in Q1 2023 and bottomed at $65.6 million in Q1 2025.
• The 5-year median for Inventory is $84.0 million (2026), against an average of $90.7 million.
• Peak annual rise in Inventory reached 67.96% in 2023, while the deepest fall reached 30.87% in 2023.
• A 5-year view of Inventory shows it stood at $129.0 million in 2022, then plunged by 30.87% to $89.1 million in 2023, then slipped by 11.93% to $78.5 million in 2024, then rose by 5.36% to $82.7 million in 2025, then grew by 1.58% to $84.0 million in 2026.
• The last three Inventory figures came in at $84.0 million (Q1 2026), $82.7 million (Q4 2025), and $75.4 million (Q3 2025), per Business Quant data.

Peer Comparison